Weekly Treatment for Children with Achondroplasia

Yuviwel (navepegritide) is a C-type natriuretic peptide (CNP) analog. On the USPI, navepegritide is a prodrug of active CNP: a CNP moiety transiently conjugated to branched mPEG via a TransCon linker. It is given as a once-weekly subcutaneous injection after reconstitution of a lyophilized powder.

Distinct from vosoritide / Voxzogo (fact-only): Vosoritide (Voxzogo) is a separate daily CNP-analog product with its own US brand, dose, and labelled use. Yuviwel is a once-weekly TransCon CNP prodrug with its own NDA and accelerated AGV label. The USPI notes that when switching from a daily CNP analog, start once-weekly Yuviwel on the day after completing the last daily CNP dose. Compare labels with the clinic; the products are not interchangeable by self-switching. This article does not invent head-to-head comparative efficacy.

The FDA approved NDA 219164 under accelerated approval on 27 February 2026 (Novel Drug Approvals for 2026 table row 5). Approval letter signed Hylton V. Joffe, MD, MMSc, Director, Office of Cardiology, Hematology, Endocrinology, and Nephrology, CDER (electronic signature HYLTON V JOFFE 02/27/2026 03:34:44 PM). NDA dated and received 31 March 2025 (major amendment 5 November 2025 extended the goal date). Applicant: Ascendis Pharma Growth Disorders (A/S) / manufactured for Ascendis Pharma Growth Disorders A/S, Hellerup, Denmark. US contact on the PI: Ascendis Pharma Endocrinology, Inc., Princeton, NJ — 1-844-442-7236 / www.YUVIWEL.com. FDA notice: priority review and accelerated approval. Approval letter also grants a rare pediatric disease priority review voucher (PRV NDA 219164) and notes orphan drug designation for this product/indication context. The application was not referred to an FDA advisory committee. Dating period on the letter: 24 months from manufacture when stored at 2–8 °C. Reference ID 5754166. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) — accelerated-approval postmarketing requirement 4969-1 is an open-label, external-controlled trial in subjects with achondroplasia ≥2 years with open epiphyses to measure the effect of Yuviwel on final adult height, with a secondary endpoint evaluating disproportionality, plus long-term safety endpoints (neurological complications, bone deformities, bone age, sleep apnea among examples on the letter). Sponsor timetable on the letter: Trial Completion 09/2034; Final Report Submission 06/2035.

Where this is taking place

Commercial labelled door today: United States — FDA accelerated approval to increase linear growth in pediatric patients ≥2 years with achondroplasia with open epiphyses. This is a pediatric endocrinology / skeletal dysplasia clinic conversation with genetic confirmation context, weight-based weekly dosing, caregiver injection training, growth monitoring, and a plan to stop at epiphyseal closure — not a casual retail pickup and not a DIY import.

Outside the United States: As of this draft, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA ARTG listing, Swissmedic authorisation, or PMDA/MHLW licence for Yuviwel / navepegritide. Company materials describe an EMA MAA under review (company-anticipated decision timing Q4 2026) — under review ≠ EC marketing authorisation. Company named-patient / international-market statements are intent only, not a licence. Do not import on your own.

ApproaCH / Trial 1 — NCT05598320 (USPI Trial 1) — Phase 2/3, randomized, double-blind, placebo-controlled 52-week period with open-label extension. Lead sponsor on ClinicalTrials.gov: Ascendis Pharma Growth Disorders A/S. CT.gov status: COMPLETED. Actual enrolment 84. Start 3 Mar 2023; actual primary completion 9 Aug 2024; actual study completion 13 Aug 2025. Study Director on the record: Medical Director, MD, Ascendis Pharma A/S. Countries with listed sites include Australia, Canada, Denmark, Ireland, New Zealand, Spain, and the United States. Canadian site on the record: Ascendis Pharma Investigational Site (Montreal) — trial geography, not a Health Canada licence. Expanded access: CT.gov record retrieved for this draft lists hasExpandedAccess: false — no expanded access listed on that record. Results are posted. The pivotal double-blind cohort that supports the accelerated label is already completed — not a new-enrolment commercial door.

Trial 2 — NCT04085523 (USPI dose-finding) — Phase 2 randomized, double-blind, placebo-controlled dose-finding with open-label extension; 57 pediatric participants on the USPI safety narrative. Supportive for dose selection / safety pooling with Trial 1; not a separate commercial enrolment path for newly labelled use.

The practical door in the US is a pediatric endocrinology / skeletal dysplasia clinician who can confirm achondroplasia with open epiphyses, age ≥2 years, teach reconstitution and weekly subcutaneous injection, set weight-based dosing from Table 1, monitor growth and blood-pressure symptoms, and discontinue at epiphyseal closure — not treating NCT05598320 as open recruitment.

Approval matrix

Access by country

• United States: Ask a pediatric endocrinology / skeletal dysplasia clinic about FDA-labelled Yuviwel. Labelled 27 February 2026 (accelerated) for pediatric patients ≥2 years with achondroplasia with open epiphyses to increase linear growth. Recommended dose: once weekly subcutaneous after reconstitution, weight-based per Table 1. Strengths: 1.3 mg, 2.8 mg, and 5.5 mg kits (carton NDCs 73362-201-01, 73362-202-01, 73362-203-01). Periodically monitor growth and adjust dose by body weight; discontinue when there is no further growth potential (epiphyseal closure). Prior authorisation and specialty-pharmacy logistics still apply. No list price or copay dollars in this article. Suspected adverse reactions: Ascendis Pharma 1-844-442-7236 or FDA MedWatch 1-800-FDA-1088. Product information: www.YUVIWEL.com. Prescribing Information / Instructions for Use: FDA label PDF. This is US commercial labelled supply, not a DIY import.

• Canada: Yuviwel authorisation not confirmed. ApproaCH lists a Montreal investigational site — trial ≠ Health Canada licence. Do not assume SAP, named-patient, or cross-border mail-order is available or appropriate. Ask the Canadian pediatric endocrinology / skeletal dysplasia clinic what legal paths exist in Canada when a Yuviwel Canadian label does not yet exist.

• European Union / United Kingdom / Australia / other countries with trial sites: Regulator authorisation not confirmed in this draft. An EMA MAA under review (company claim) is not a licence. Completed ApproaCH participation is not a commercial Yuviwel label.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US kit as a foreign carton. Company named-patient intent statements are not a licence.

Who is eligible (from the US label)

This is a pediatric achondroplasia with open epiphyses conversation on the USPI — ≥2 years — to increase linear growth under accelerated approval.

United States (USPI, revised / issued February 2026):

• Indication: Increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
• Accelerated approval honesty: Based on an improvement in annualized growth velocity. Continued approval may be contingent on confirmatory trial(s).
• Recommended dosage: Once-weekly subcutaneous injection; dose by body weight (Table 1). Must reconstitute before use. Caregivers/patients should receive training before use.
• Table 1 examples (weekly dose by weight): 8–9.9 kg → 0.88 mg; 10–13.4 kg → 1.2 mg; 13.5–17.5 kg → 1.6 mg; 17.6–23 kg → 2.1 mg; 23.1–30.5 kg → 2.8 mg; 30.6–41.2 kg → 3.6 mg; 41.3–55.9 kg → 5 mg; 56–73.5 kg → 6.6 mg (two kits); 73.6–90 kg → 8.8 mg (two kits). Use the vial strength specified in Table 1.
• Monitor growth; adjust dose with weight; discontinue at epiphyseal closure.
• Injection sites: abdomen (2 inches from belly button) or thighs; caregiver may also use buttocks or back of upper arm. Rotate sites.
• Missed dose: Give as soon as possible but not more than 2 days after the missed dosing day; Yuviwel can be taken up to 2 days before or after the scheduled day; if more than 2 days have passed, skip and resume on the next scheduled day; at least 5 days should elapse between doses.
• Switching from daily CNP analog: Start Yuviwel on the day after the last daily CNP dose.
• Contraindications: None.
• Renal impairment: Not recommended if eGFR <60 mL/min/1.73 m² (moderate or severe). Mild renal impairment: same as normal renal function.
• Pediatrics <2 years: Safety and effectiveness not established.
• Trial context (Trial 1): genetically confirmed achondroplasia; treatment-naïve on the USPI efficacy narrative; mean age about 5.7 years (range 2–12) in the Trial 1 safety description.

Not labelled on sources confirmed for this draft:

• Children younger than 2 years.
• Use after confirmed epiphyseal closure.
• EU, UK, Canadian, Japanese, Australian, or Swiss Yuviwel marketing authorisations (not confirmed here).
• Using Yuviwel as a free swap for vosoritide without a clinician reading both labels.
• Treating completed ApproaCH as open commercial enrolment.

What the pivotal study showed (ApproaCH / Trial 1 / USPI)

Use the USPI for a US prescription conversation. Journals and conference abstracts are supportive reading. AGV supported accelerated approval; final adult height confirmatory work continues under PMR 4969-1.

Trial 1 — NCT05598320 (ApproaCH):

• Randomized, double-blind, placebo-controlled 52-week period; 84 treatment-naïve pediatric patients with genetically confirmed achondroplasia: navepegritide 0.1 mg/kg/week (n=57) vs placebo (n=27).
• Primary efficacy endpoint: AGV at Week 52. Height Z-scores (achondroplasia-specific and CDC-based) also evaluated.
• Mean baseline CDC-based height Z-score about -5.0 on the USPI narrative.

USPI Table 4 (LS means at Week 52):

FDA notice plain language: patients receiving Yuviwel grew an average of 1.5 centimeters taller over 52 weeks compared with placebo; open-label extension maintained the rate of height growth during a second year of treatment among those who received two years of Yuviwel.

Trial-status honesty: Trial 1 is COMPLETED and supports the US accelerated label. That is not a door for new commercial starters outside labelled US distribution. No expanded access is listed on the CT.gov record retrieved for this draft. Confirmatory final adult height work (PMR 4969-1) is still required.

How it is taken (US label — keep this exact)

Safety (what the label puts first)

Contraindications: None.

Risk of low blood pressure: Transient decreases in blood pressure have been reported with a once-daily CNP analog. Patients with hemodynamically significant cardiovascular disease were excluded from navepegritide trials. Advise contacting the clinician for symptoms of decreased blood pressure (for example dizziness, fatigue, and/or nausea; FDA notice also lists lightheadedness, fainting, blurred vision).

Most common adverse reactions (≥5% and ≥2% higher than placebo in pooled Trials 1 and 2 at 0.1 mg/kg/week): vomiting (21% vs 14%), injection-site reaction (19% vs 14%), pain in extremity (12% vs 7%), nausea (6% vs 0%).

Injection-site reactions: 13/68 (19%) on navepegritide vs 6/42 (14%) on placebo in the pooled double-blind periods; rotate injection sites.

Hypertrichosis: reported in 3% on navepegritide vs none on placebo in the pooled double-blind periods (localized at injection sites or more generalized); rotate sites to reduce local skin changes.

Report suspected adverse reactions to Ascendis Pharma 1-844-442-7236 or FDA MedWatch 1-800-FDA-1088.

No boxed warning on the PI retrieved for this draft. That is not “no risk” — blood-pressure symptoms, injection-site reactions, vomiting, limb pain, and nausea are the main labelled safety story on the highlights path.

How to talk to a doctor

Bring the brand, the INN, the NDA / NCT numbers, and the US Prescribing Information / Instructions for Use if you are in a US clinic. Outside the US, bring honesty that a local Yuviwel label may not exist yet.

1. “My child is ≥2 years old with achondroplasia and open growth plates. The FDA gave accelerated approval to Yuviwel (navepegritide) on 27 February 2026. Is that labelled for us in this country?”
2. “This is a once-weekly subcutaneous CNP analog, a separate product from vosoritide (Voxzogo). Can we compare labels and decide together — without self-switching?”
3. “The labelled dose is weight-based once weekly after reconstitution. Who will train us on reconstitution and injection, and how often will weight / growth be checked?”
4. “Trial 1 / ApproaCH (NCT05598320) showed an LS-mean AGV difference of 1.5 cm/year and an achondroplasia-specific height Z-score increase of 0.3. I understand accelerated approval means final adult height confirmatory results (PMR 4969-1, letter timetable through 2034/2035) are still required — what does that mean for our care plan?”
5. “Please cover blood-pressure symptoms (dizziness, fatigue, nausea) and when we should call.”
6. “Please cover injection-site reactions, vomiting, limb pain, and nausea, and how we rotate sites.”
7. “When should we plan to stop because growth plates have closed?”
8. “If we are switching from a daily CNP analog, the label says start Yuviwel the day after the last daily dose — does that apply to us?”
9. “Is prior authorisation started? Who coordinates the kits (NDCs 73362-201-01 / 202-01 / 203-01) and refrigeration logistics?”
10. “Ex-US Yuviwel authorisations are not confirmed on the sources we are using (an EMA MAA under review is not a licence). We will not import a foreign carton.”

Research and regulatory team (from sources only — no invented contacts)

Names and roles as they appear on primary sources — not a clinic directory.

• Ascendis Pharma Growth Disorders A/S, Tuborg Boulevard 12, DK-2900 Hellerup, Denmark — NDA 219164 applicant; PI “Manufactured for”.
• Ascendis Pharma Endocrinology, Inc., Princeton, NJ — labelled US contact 1-844-442-7236 / www.YUVIWEL.com (product information / AE reporting path on PI — not a treating clinic).
• Ascendis Pharma Growth Disorders A/S — ClinicalTrials.gov lead sponsor for NCT05598320.
• Medical Director, MD, Ascendis Pharma A/S — Study Director on the CT.gov record for ApproaCH (org title only on the record retrieved — not a named personal referral desk).
• David Cho, MS — Associate Director, Regulatory Affairs — addressee on the NDA approval letter (corporate regulatory contact, not a treating clinic).
• Hylton V. Joffe, MD, MMSc — Director, Office of Cardiology, Hematology, Endocrinology, and Nephrology, CDER — signed the 27 February 2026 approval letter.
• Melissa Button — FDA Regulatory Project Manager named on the approval letter (agency contact, not a patient hotline).
• Site-level hospital phone numbers are not listed here — ask your own pediatric endocrinology / skeletal dysplasia clinician. Named personal overall PIs beyond the Study Director org title were not listed on the NCT05598320 API record retrieved for this draft.

Canada zoom: Yuviwel not confirmed

There is no retrieved Health Canada Notice of Compliance or DIN for Yuviwel / navepegritide on the sources used for this draft. US FDA accelerated approval does not create a Canadian Product Monograph. ApproaCH lists a Montreal investigational site — that is trial geography, not a licence. Do not treat cross-border mail-order of a US kit as the care plan. Ask a Canadian pediatric endocrinology / skeletal dysplasia clinician what legal options exist while waiting for any future Canadian Yuviwel decision.

Bottom line

Yuviwel (navepegritide) is an FDA-approved once-weekly subcutaneous CNP analog — labelled 27 February 2026 under accelerated approval (NDA 219164) to increase linear growth in pediatric patients ≥2 years with achondroplasia with open epiphyses. Dose is weight-based once weekly after reconstitution (1.3 / 2.8 / 5.5 mg kits). ApproaCH / Trial 1 (NCT05598320) showed an LS-mean AGV difference of 1.5 cm/year and achondroplasia-specific height Z-score increase of 0.3; final adult height confirmatory work continues under PMR 4969-1 (letter timetable completion 09/2034, final report 06/2035). Watch blood-pressure symptoms, injection-site reactions, vomiting, limb pain, and nausea. US labelled. Other major regulators not confirmed. An EMA MAA under review is not a foreign licence. Distinct weekly TransCon CNP product from daily vosoritide — compare labels; do not self-swap. The door is a pediatric endocrinology / skeletal dysplasia clinic writing the US label with injection training — a completed pivotal cohort is not a new commercial enrolment path. Authorized is not funded.

---

Primary sources

1. FDA Novel Drug Approvals for 2026 — Yuviwel / navepegritide, approval date 2/27/2026, row 5 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
2. FDA human-drugs notice — FDA Approves Drug for Pediatric Patients with the Most Common Form of Dwarfism — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-patients-most-common-form-dwarfism
3. FDA Prescribing Information PDF, NDA 219164 — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
4. FDA NDA accelerated approval letter, NDA 219164, signed Hylton V. Joffe, MD, MMSc, 27 February 2026, Reference ID 5754166 — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219164Orig1s000ltr.pdf
5. ClinicalTrials.gov NCT05598320 — ApproaCH / Trial 1 — https://clinicaltrials.gov/study/NCT05598320
6. ClinicalTrials.gov NCT04085523 — Trial 2 dose-finding (USPI) — https://clinicaltrials.gov/study/NCT04085523
7. Product / AE contact on PI — www.YUVIWEL.com / 1-844-442-7236 (labelled contact, not a prescribing desk)